Lactobacillus gasseri LA806 Supplementation in Patients with Irritable Bowel Syndrome: A Multicenter Study

• Published in: Journal of clinical medicine Vol. 11; no. 24; p. 7446
• Main Authors: Ait Abdellah, Samira, Scanzi, Julien, Gal, Caroline, Martin, Marc, Beck, Marc, Ojetti, Veronica
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 15-12-2022; MDPI
• Subjects: Abdomen; Clinical medicine; Constipation; Diarrhea; Disease; Gastroenterology; Irritable bowel syndrome; Microbiota; Observational studies; Pain; Pathophysiology; Patients; Permeability; Probiotics; Quality of life; Questionnaires; Stress; France; microbiota; abdominal pain; quality of life; functional disease; irritable bowel syndrome; probiotics
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm11247446

The potential benefits of Lactobacillus gasseri LA806 in IBS were previously identified in a comprehensive preclinical research program. The purpose of this multicenter study was to explore in real-life conditions changes in IBS symptoms and quality of life in patients receiving a 4-week supplementation with L. gasseri LA806. Altogether 119 patients meeting Rome IV criteria for IBS were included, of whom 118 received the supplement. The majority of patients (71.8% (95% CI 63.6−79.9%)) manifested a ≥30% decrease in abdominal pain at 4 weeks, the mean abdominal pain score diminishing by 54.2% (from 5.3 ± 2.2 to 2.2 ± 2.4, p < 0.0001). A statistically significant decrease in abdominal pain was seen as early as the first week. A decrease of ≥30% in both abdominal pain score and global IBS symptom score was attained in 61.5% of patients (95% CI 51.7−71.2%). The mean IBS-SSS score fell by 152 ± 112 points (p = 0.001), with symptoms being attenuated in 85% of patients (CGI-I). Supplementation led to a 10-fold decrease in the number of patients reporting severe IBS symptoms. The concomitant intake of antidiarrheals, antispasmodics and analgesics decreased and quality of life scores significantly improved. These preliminary results warrant confirmation by a randomized, placebo-controlled study that this study will allow a better design.